Metastatic cancer of unknown primary: diagnostic challenges

CAP TODAY and the Association for Molecular Pathology have teamed up to bring molecular case reports to CAP TODAY readers. AMP members write the reports using clinical cases from their own practices that show molecular testing’s important role in diagnosis, prognosis, and treatment. Case report No. 11, which begins here, comes from Cooper Medical School at Rowan University and Cooper University Hospital, Camden, NJ. If you would like to submit a case report, please send email to the AMP at amp@amp.org. For more information about the AMP and all previously published case reports, visit www.amp.org.

Erica Schramm  
William Kocher, MD  
Tina Bocker Edmonston, MD

Case presentation. A 75-year-old man presented in the emergency department with the complaint of right shoulder pain for the prior three weeks, which was subsequently found to be due to a displaced clavicular fracture with no apparent history of trauma. His past medical history was significant for hypertension, diabetes, hypercholesterolemia, chronic obstructive pulmonary disease, aortic stenosis, and a high-grade superficially muscle-invasive carcinoma of the prostatic urethra diagnosed at an outside hospital two years prior. The cancer had been treated with platinum-based chemotherapy and radiation with complete response. In the emergency department, the patient was noted to be hypoxemic, and laboratory studies were significant for hypercalcemia, mildly elevated creatinine, abnormal liver function studies, and mild anemia. The patient was admitted for further evaluation.

Additional laboratory testing suggested a paraneoplastic etiology for the patient’s hypercalcemia. Serum and urine protein electrophoreses were normal. An ultrasound suggested a liver mass; however, this finding could not be confirmed definitively by CT scan. Subsequent imaging studies demonstrated radiolucent lesions involving ribs and thoracic spine, raising concern for metastatic disease. The main differential diagnoses for lytic bone metastases included squamous cell carcinoma of the lung, renal cell carcino-

![Fig. 1. (A), (B): H&E of sections of a liver nodule show pleomorphic small blue round tumor cells growing in nests and trabeculi, suggesting a poorly differentiated neuroendocrine carcinoma. Mitoses are present. Tumor cells are completely negative for (C) S-100, (D) synaptophysin, and (E) chromogranin.](image-url)
Rhabdomyosarcoma

Fig. 4, Fig. 1, Fig. 2

Histology showed metastatic poorly differentiated carcinoma with neuroendocrine features. The histology of the tumor found at autopsy did not provide any clues as to the origin. A paraffin block of the tumor was sent to a commercial laboratory (Rosetta Genomics) for its Cancer Origin Test.

The test uses microRNA expression microarrays for the quantification of 64 microRNAs. Two classifiers are applied to determine the tissue of origin of the unknown primary. These classifiers were developed using microRNA profiles of a training set of 1,282 known and well-characterized tumors. A binary decision tree chooses the left or right branch based on the expression level and preset thresholds of one to three microRNAs at each node (Fig. 2). A second classifier, the K-nearest-neighbor (KNN), compares the expression across all 64 microRNAs to the data set of the 1,282 training samples and selects the majority diagnosis among the nearest five samples (Fig. 3, page 3). The binary decision tree and the KNN independently predict one of 42 tumor types, and in 82 percent of cases they agree on the tumor origin. For these cases, the accuracy of the molecular classification is 90 percent. In cases of disagreement between the binary decision tree and KNN, two possible cancers of origin are reported and ranked according to the calculated confidence measure of the two classifiers. In the reported case, the decision tree and KNN did agree and identified the metastases to be of urothelial origin. Additional immunohistochemical stains for uroplakin and GATA3 were subsequently performed and were positive, confirming the molecular result (Fig. 4, page 4). Cause of death was therefore determined to be widespread metastatic urothelial cell carcinoma.

Discussion. Cancer of unknown primary, or CUP, often serves as a catchall diagnosis for metastatic cancer when a primary site has not been identified despite an extensive clinical and pathology workup, as in our case. It has been estimated that CUP makes up three to five percent of all new cancer diagnoses each year in the United States (about 50,000 to 70,000 new cases per year). The prognosis for patients with CUP is poor. Median survival from diagnosis is generally only three to four
months, with one-year survival of 25 percent and five-year survival of 10 percent. About 60 percent of cancers of unknown primary are well to moderately differentiated adenocarcinoma, 30 percent are poorly differentiated adenocarcinoma or poorly differentiated carcinoma, five percent are squamous cell carcinomas, and five percent are poorly differentiated or undifferentiated malignant neoplasms.

CUP presents a challenging diagnostic dilemma for pathologists. By definition, extensive testing often does not reveal a clear tissue of origin. Even postmortem examination fails to identify the primary site in 15 to 25 percent of patients. For each individual patient, an exhaustive workup may ultimately include CT, MRI, PET scan, endoscopies, serum tumor markers, gross tumor morphology, pattern of spread, light microscopy, and immunohistochemistry. However, in about 30 percent of cases of cancer of unknown primary, the staining pattern does not give a final diagnosis. Patients whose primary cancer cannot be identified are often treated with empiric systemic platinum-based therapy, rather than chemotherapy specifically directed toward the underlying cancer. Studies suggest that only 25 to 35 percent of CUP respond to empiric therapy, increasing the median survival to nine months.

Molecular expression profiles based on RT-PCR or microarray analysis of tumor mRNA or microRNA have been developed in an attempt to streamline diagnosis and create a more objective diagnostic test. These tests are validated to generate a molecular profile of the metastasis or unknown cancer and identify a tissue of origin by comparing the molecular profile of the “unknown” with the profiles of previously established known tumors. Several such tests are commercially available.

Our case illustrates the potential of molecular testing to identify the origin of a CUP when other testing such as imaging and traditional histopathology fails to give a clear diagnosis. Based on the patient’s history, metastatic urothelial carcinoma was in the differential diagnosis, but other primary tumors that are more likely to cause lytic bone metastases could not be ruled out. Another challenge was that no biopsy of the metastases could be obtained during the lifetime of this patient. Even the autopsy results (gross tumor morphology, light microscopy, and immunohistochemical staining) were inconclusive for a cancer of origin, and urothelial cancer was not suspected based on histomorphology. The microRNA-based tumor profile, however, unambiguously identified urothelial carcinoma as the primary origin, demonstrating the utility of such an assay not only for identifying the tumor of origin in typical CUP but also for revealing a primary tumor that is not considered during the initial immunohistochemical workup of a tumor.

In retrospect, a small biopsy of sufficient size for molecular tumor profiling could possibly have been obtained, since molecular CUP tests require less tissue compared with what may be needed for a comprehensive IHC workup. The impact of identifying the primary in a patient with CUP was demonstrated in a recent prospective study that used a real-time RT-PCR assay to determine the tumor of origin in 247 patients with cancer of unknown primary. In the study, 194 patients received assay-directed, site-specific treatment. Median survival time for these patients was found to be 12.5 months, which compares favorably to nine months for CUP patients treated empirically. While this study suggests the potential of novel molecular diagnostic tests to direct treatment of cancers of unknown primary, there are relatively few studies of its kind, and no one molecular assay for the identification of tumor origin has

![Fig. 3. K-nearest-neighbor (KNN) from Rosetta Cancer Origin Test (courtesy of Rosetta Genomics). The full KNN analysis compares the expression across all 64 microRNAs used for the test on the 1,282 training samples. The majority diagnosis among the nearest five samples is determined. This figure shows a simplified version of KNN results in three-dimensional space. Only the expression of three microRNAs (instead of 64 microRNAs) and only the most likely differential diagnoses (instead of all 1,282 tumors in the training set) are shown. Our patient sample is depicted as a blue dot. The five nearest neighbors in the complete training set are marked with a black dot on top of the symbol representing the reference diagnosis. Four of the nearest neighbors were urothelial carcinomas, and one of the nearest neighbors was a biliary tract cancer. (TCC: urothelial carcinoma, SqCC: squamous cell carcinoma, hsa-miR-205, hsa-miR-375, hsa-miR-934: three microRNAs selected for this image.)](image)
been adopted as standard of care in clinical practice. In addition, two prospective blinded studies suggest superior accuracy of molecular CUP testing compared with extended IHC panels,9,10 and turnaround times of five to 10 days for the molecular profiles should fulfill the clinical need in conjunction with traditional pathology testing.

**Conclusions.** A microRNA-based molecular assay for cancer of unknown primary correctly identified urothelial carcinoma as the primary cancer in this patient with widely metastatic disease. Such tests can be performed on small biopsies and help guide patient management in conjunction with traditional pathology/IHC and imaging studies. In particular, patients who are found to have a tissue of origin that is known to be responsive to site-specific treatment will be expected to achieve longer survival times compared with empiric treatment for CUP.

---


---

**AMP case report**

**Test yourself**

Here are three questions taken from the case report. Answers are online now at www.amp.org/casereviews and will be published next month in CAP TODAY.

1. How can a tumor of unknown primary be identified?
   a) Clinically by typical distribution pattern and location for the primary.
   b) IHC panels.
   c) Imaging studies (CAT scan, MRI, PET).
   d) Endoscopy.
   e) Molecular profiling of a metastasis.
   f) All of the above.

2. Which of the following statements regarding cancer of unknown primary (CUP) is correct?

   a) CUP comprises about three to five percent of all new cancer diagnoses in the United States.
   b) Median survival from diagnosis is generally only three to four weeks.
   c) The vast majority of CUP are poorly differentiated and undifferentiated carcinomas.
   d) If a primary cannot be identified, the patient does not qualify for chemotherapy.

3. Molecular tests for the identification of CUP:
   a) May analyze the expression of mRNA or microRNA.
   b) Compare the molecular profile of the “unknown” with the profiles of previously established known tumors.
   c) Can successfully be performed on small biopsies.
   d) All of the above.